On September 24, 2025, Dr. Maen Hussein, a medical oncologist and hematologist, held an important meeting with His Majesty King Abdullah II of Jordan, alongside the Jordanian American Physicians Association (JAPA) representatives. This event took place just before the United Nations General Assembly in New York City and marks the second time Dr. Hussein has met with the King to discuss pivotal healthcare collaborations between Jordanian professionals in the U.S. and those in Jordan.
Dr. Hussein, who also serves as the president of JAPA, emphasized the meeting's significance, stating, "Our discussion reaffirmed the association’s primary goal of fostering collaboration among Jordanian medical practitioners in the U.S. and their counterparts back home. This partnership is crucial for enhancing healthcare development and nurturing the next wave of medical professionals."
During their dialogue, King Abdullah II commended the contributions of Jordanian doctors in the U.S. He highlighted their role in improving Jordan’s status in the medical field, as well as their commitment to serving communities both domestically and internationally. The King emphasized the importance of ongoing cooperation and exchange of knowledge to bolster Jordan's healthcare sector and support its modernizing goals.
Also on the agenda were discussions concerning the challenges faced by Jordanian physicians in foreign countries, as well as potential collaboration opportunities to advance Jordan's healthcare system further. Dr. Hussein noted his and his colleagues' gratitude for the King's continuous support and his commitment to the Jordanian diaspora, with an affirmation to contribute to Jordan's healthcare sector through training programs, mentorships, and volunteer efforts.
Dr. Maen Hussein has been actively involved with JAPA since its inception in 2014. Initially founded as a virtual platform for physicians seeking to connect and support the healthcare needs of their home country, JAPA has made significant strides, including:
- - Delivering $250,000 worth of medical supplies and protective gear to Jordan’s Ministry of Health and university hospitals during the pandemic.
- - Providing hundreds of interest-free loans to students and facilitating training placements for Jordanian medical students in the U.S. through sustainable initiatives worth several hundred thousand dinars.
- - Organizing medical missions, even under challenging conditions, to provide specialized care in Gaza.
- - Raising over $600,000 to support the King Hussein Cancer Foundation, specifically for treating children with cancer from Gaza.
- - Conducting annual conferences and workshops both in Jordan and the U.S. to promote medical education and collaborative efforts.
- - Establishing endowments to assist patients and creating a global network of physicians and medical students.
Dr. Lucio N. Gordan, president and managing physician at Florida Cancer Specialists (FCS), praised Dr. Hussein’s leadership, stating, "Dr. Hussein’s expertise and visionary approach extend far beyond our local borders. He exemplifies how to inspire innovation and collaboration to impact communities globally."
Expressing his appreciation for the support of FCS, where he has practiced since 2011, Dr. Hussein remarked, "Being part of this organization allows me the opportunity to extend my impact so that cancer patients receive the best possible care."
In his leadership role at FCS, Dr. Hussein oversees the continuous development of value-based care initiatives aimed at improving patient outcomes while effectively managing costs. An active cancer researcher, he has led numerous clinical trials focused on lung cancer, with his research widely published and presented at key industry events. Additionally, Dr. Hussein serves as president of the Florida Society of Clinical Oncology (FLASCO) and has been a member of the board of directors and the immediate past chair of the FCS Foundation.
Florida Cancer Specialists and Research Institute, established over 40 years ago, has been at the forefront of oncology care and research, providing patients access to essential clinical trials. The organization plays a critical role in the development and management of groundbreaking cancer treatments, making them available to patients ahead of the standard FDA approval process. Their team of highly trained physicians is dedicated to delivering personalized treatment plans that utilize cutting-edge advancements in precision oncology to improve patient outcomes.